Adis announces summer training schedule

Adis has just published a schedule of open access training sessions taking place over the coming months for the AdisInsight databases.

These introductory training sessions are designed to help users and subscribers make the most of the AdisInsight suite of drug development, clinical trials and drug safety databases. Participation is recommended for anyone interested in finding out more about the databases, new users, and existing users who may be looking to refresh their knowledge.

The trainer will provide participants with a background on each database, the content, how to run searches and set up alerts, as well as giving some useful tips on how to make the most of tools available.

Each session is hosted online and all you need to participate is an internet connection and access to a telephone. You will be able to watch the presentation on your desktop and you will be provided with a toll-free phone number to dial in should you wish to ask questions during the session.

To view the schedule of upcoming sessions, or to register, please visit the training page.

Reactions Weekly newsletter publishes 1,500th issue

Adis, the leading publisher of drug safety and pharmacovigilance content, has been publishing expert summaries of drug safety news for over 30 years.

Another Adis title reached a significant milestone this week when it published its 1,500th issue on SpringerLink.

Reactions Weekly is an online publication focusing on adverse drug reactions and drug safety news. The newsletter, which includes news from The Uppsala Monitoring Centre, has been publishing summaries of the world’s adverse drug reaction news and case reports for more than 30 years.

The weekly newsletter provides a round-up of news including labelling changes, drug withdrawals due to safety issues, adverse reaction research and current issues in drug safety. Content is sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme. Each report is read and summarized by a member of the expert editorial team.

Editor, Suzanne Berresford, states:

“I think I speak on behalf of the whole Reactions team when I say that I am very proud to work on a publication that has truly stood the test of time. Reactions Weekly has been through a lot of changes since its launch in the 1980s, shifting from print publication to purely online, for example, in response to our changing customer needs. One thing is clear though – the service we provide in summarizing news and case reports so that they are quick and easy-to-read is even more valuable today as our readers are under increasing time pressure in their roles”.

Reactions Weekly is part of a suite of pharmacovigilance and drug safety solutions from Adis that also includes the Drug Safety journal, Pharmacovigilance Insight database and the Reactions Pharmacovigilance Service.

Browse the latest issue of Reactions Weekly online or read more on

Adis launches two new Open Access journals

Adis, a leading global provider of drug information, has just announced the launch of two new open access journals, which will be added to their portfolio in Summer 2014.

Drugs – Real World Outcomes

The first new title to be launched is Drugs – Real World Outcomes. The journal will focus on the performance of drugs in day-to-day clinical practice, and the use of real-world data to support evaluation of health outcomes. Investigations into drug utilization, patterns of prescribing, treatment guideline adherence, and comparative effectiveness and economic analyses will all fall under the scope of this new title.

Dene Peters, Co-Editor, explains:

“We all know that the gold standard in research is the randomized controlled clinical trial; however, we also know that these trials by the nature of their design fail to inform clinicians on many fronts. While they provide vital confirmation of efficacy and safety, they exclude many relevant patient groups, such as the elderly, children and those with co-morbidities, and they are conducted in ideal settings, with an expectation of high adherence rates. Clinicians need to know how their patients will respond to a drug in real life – and the potential impact of factors such as race, age, sex, co-morbidities, performance status and other medications. Our new journal aims to address this by providing a vehicle for dissemination and a forum for discussion of these issues”.

Co-Editor Anton van Rensburg adds:

“We are excited about the contribution the journal will be able to make to clinical practice by providing meaningful information for critical decision making and are pleased to invite researchers to submit their original research and definitive reviews to the title for consideration.”

Drug Safety – Case Reports

Drug Safety – Case Reports is the second new title being added to the Adis portfolio and is a sister publication to the well-established Drug Safety journal, also published by Adis. This new title will specialize in the publication of case reports and case series related to suspected adverse drug reactions (ADRs) following the use of one or more conventional drugs, vaccines, herbal/complementary medicines, biologics, commercially-prepared blood products, diagnostic pharmaceuticals, and drug-device combination products.

Co-Editor Nitin Joshi announced:

“Although Drug Safety has been serving the needs of `Pharmacovigilantes’ since 1986, the need to cater to our diverse readership precluded us from publishing case reports on a regular basis. To cover this gap and to acknowledge the importance of published case reports in pharmacovigilance, we decided to launch Drug Safety – Case Reports”

Fellow Co-Editor Steve McMillan states:

“The field of pharmacovigilance is rapidly developing and we are pleased to be able to offer another valuable source of information for both healthcare professionals and manufacturers, to add to our already strong portfolio of content solutions”.

Both of the new journals will be published under the AdisOpen program meaning that they will be published online only and will be entirely open access, making them accessible to readers globally without the need for a subscription. All articles published in the journals will undergo rigorous peer review to ensure that they meet the high standards expected from Adis.

Adis has more than 40 years’ experience in publishing, with a portfolio of more than 30 medical journals and newsletters. As part of Springer, they are able to offer many benefits to authors including efficient article submission, tracking and review, expedited publication timelines, and high visibility through Springer’s proprietary content platforms. More information about the two new journals will be announced soon via the website. For any inquiries in the meantime, please contact the Editorial team at